SCHEMBL327954

SCHEMBL327954

CNC(C)c1ccc(OC)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.56
CA2 P00918 2/20 0.56
ACHE P22303 1/20 0.56
ALDH1A1 P00352 4/20 0.53
CYP2D6 P10635 1/20 0.53
CA12 O43570 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
CA14 Q9ULX7 1/20 0.50
ACACB O00763 1/20 0.49
MAPK1 P28482 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
TSHR P16473 1/20 0.47
PKM P14618 1/20 0.46
KDM1A O60341 1/20 0.46
RAB9A P51151 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
ACP3 P15309 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13462356 1.00 CA1 (0.56) CA1CA2ACHEALDH1A1CYP2D6
SCHEMBL8239398 1.00 CA1 (0.56) CA1CA2ACHEALDH1A1CYP2D6
Hydrochloric Acid SCHEMBL3654829 0.98 CA1 (0.55) CA1CA2ACHEALDH1A1CYP2D6
SCHEMBL28660520 0.84 CA1 (0.58) CA1CA2ACHEALDH1A1CA12
SCHEMBL24258312 0.82 ALOX5 (0.60) CYP2D6TDP1L3MBTL1TSHRMAPT
SCHEMBL28277742 0.82 CA1 (0.56) CA1CA2ACHEALDH1A1CA12
SCHEMBL24105692 0.82 CA1 (0.56) CA1CA2ACHEALDH1A1CYP2D6
SCHEMBL19286211 0.82 CA1 (0.56) CA1CA2ACHEALDH1A1CA12
SCHEMBL8284262 0.80 ACACB (0.50) ALDH1A1CYP2D6ACACBMAPK1MEN1
SCHEMBL24105676 0.80 CA1 (0.55) CA1CA2ACHEALDH1A1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1656349-B1 CYCLOPROPYL DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS LUNDBECK & CO AS H (DK) 2011-10-12 EP claimed
CN-119040223-B Lactobacillus rhamnosus RH22 with anti-inflammatory and antiallergic effects and application thereof 微康益生菌(苏州)股份有限公司 2025-02-28 CN disclosed
CN-119040223-A Lactobacillus rhamnosus RH22 with anti-inflammatory and antiallergic effects and application thereof 微康益生菌(苏州)股份有限公司 2024-11-29 CN disclosed
CN-114632136-B Skin external composition with enhanced anti-rash effect 浙江养生堂天然药物研究所有限公司 2024-09-27 CN disclosed
CN-118453459-A Fermentation product extract and preparation method and application thereof 浙江立恩生物科技有限公司 2024-08-09 CN disclosed
CN-114948801-B Protective composition with relieving effect and preparation method thereof 深圳减字科技有限公司 2024-04-30 CN disclosed
CN-117357418-A Use of natural products in soothing anti-sensitization cosmetics and anti-sensitization drugs 上海致臻志臣科技有限公司 2024-01-09 CN disclosed
CN-116891515-A Antiallergic peptide and application thereof in immune regulation and antiallergic 绿茵生技股份有限公司 2023-10-17 CN disclosed
CN-116785296-A PLK1 inhibitor and application thereof 河北渤腾医药技术有限公司 2023-09-22 CN disclosed
CN-113662869-B Compound for promoting extracellular matrix gene expression and preparation method thereof 南京斯拜科生物科技股份有限公司 2023-09-15 CN disclosed
WO-2008099994-A1 BIPHENYL DIOL DERIVATIVES AND COMPOSITIONS COMPRISING THE SAME AS AN ACTIVE INGREDIENT BIOSPECTRUM INC. (KR) 2008-08-21 WO disclosed
EP-1909581-A2 ADIPOSE TISSUE STEM CELLS, PERIVASCULAR CELLS AND PERICYTES UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2008-04-16 EP disclosed
US-20070197522-A1 Dpp-iv inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2007-08-23 US disclosed
US-7247648-B2 N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones THE PROCTER & GAMBLE COMPANY (US) 2007-07-24 US disclosed
WO-2007019107-A2 ADIPOSE TISSUE STEM CELLS, PERIVASCULAR CELLS AND PERICYTES UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2007-02-15 WO disclosed
US-20040097560-A1 N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones THE PROCTER & GAMBLE COMPANY 2004-05-20 US disclosed
EP-0034415-B1 1-(CYCLOHEXYL OR CYCLOHEXENYL)-4-ARYL-4-PIPERIDINECARBOXYLIC ACID DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1984-05-30 EP disclosed
US-4369184-A ANTIHISTAMINES; HETEROCYCLIC NITRILES JANSSEN PHARMACEUTICA N.V. (BE) 1983-01-18 US disclosed
EP-0034415-A1 1-(Cyclohexyl or cyclohexenyl)-4-aryl-4-piperidinecarboxylic acid derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1981-08-26 EP disclosed
US-4134980-A Phenylalkylamino-alkyl derivatives of quinazolinone and phthalazinone BOEHRINGER INGELHEIM GMBH (DE) 1979-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097560-A1 N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones IL17A, CYP51A1, CD4 CA1 4833/4885CA2 4713/4885ACHE 2865/4885
US-20070197522-A1 Dpp-iv inhibitors DPP7, DPP4, DPP3 CA1 2245/4885CA2 410/4885ACHE 180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.